<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN" "JATS-archivearticle1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JPSIM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Pakistan Society of Internal Medicine</journal-title>
        <abbrev-title>J Pak Soc Intern Med</abbrev-title>
      </journal-title-group>
      <issn publication-format="print">2709-8729</issn>
      <issn publication-format="electronic">2710-0804</issn>
      <publisher>
        <publisher-name>Pakistan Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.70302/jpsim.v7i4.2671</article-id>
      <article-id pub-id-type="publisher-id">jpsim.v7i4.2671</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="section">
          <subject>Gastroenterology &amp; Hepatology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Voice of Copper: Wilson’s Disease Presenting with Progressive Dysarthria and Cirrhosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Batool</surname>
            <given-names>Maha</given-names>
          </name>
          <email>mahabatool16@gmail.com</email>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Babar</surname>
            <given-names>Farah</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Irfan</surname>
            <given-names>Minahil Binte</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akram</surname>
            <given-names>Imman</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sheikh</surname>
            <given-names>Minahil Tariq</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Imran</surname>
            <given-names>Muhammad</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <institution>Department of Medicine, Gulab Devi Hospital, Lahore</institution>
        <country>Pakistan</country>
      </aff>
      <author-notes>
        <corresp id="cor1">*Correspondence: Maha Batool (mahabatool16@gmail.com)</corresp>
        <fn fn-type="conflict">
          <p>None</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-11-20">
        <day>20</day>
        <month>11</month>
        <year>2026</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2026</year>
      </pub-date>
      <volume>7</volume>
      <issue>4</issue>
      <fpage>355</fpage>
      <lpage>358</lpage>
      <history>
        <date date-type="received" iso-8601-date="2026-04-15">
          <day>15</day>
          <month>04</month>
          <year>2026</year>
        </date>
        <date date-type="rev-recd" iso-8601-date="2026-08-18">
          <day>18</day>
          <month>08</month>
          <year>2026</year>
        </date>
        <date date-type="accepted" iso-8601-date="2026-10-28">
          <day>28</day>
          <month>10</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright © 2026 The Author(s)</copyright-statement>
        <copyright-year>2026</copyright-year>
        <copyright-holder>The Author(s)</copyright-holder>
        <ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://psimj.com/article/jpsim.v7i4.2671" content-type="text/html"/>
      <abstract>
        <p>Wilson’s disease (WD) is a rare autosomal recessive disorder of copper metabolism arising from pathogenic variants in the ATP7B gene. The resulting impairment in biliary copper excretion leads to progressive copper deposition in the liver, brain, cornea, and other organs, producing a heterogeneous clinical syndrome encompassing hepatic, neurological, psychiatric, and ophthalmological features. We report a 25-year-old male who presented with a one-year history of progressive dysarthria and abdominal distension. Clinical evaluation revealed bilateral Kayser–Fleischer rings, markedly reduced serum ceruloplasmin (5 mg/dL), elevated 24-hour urinary copper excretion (328.3 μg/24 h), biochemical evidence of chronic liver disease, and characteristic T2 hyperintensities of the basal ganglia, thalami, and midbrain on brain MRI. The Leipzig scoring system yielded a score of 8, establishing a definitive diagnosis of WD.This case highlights the importance of maintaining a high index of suspicion for Wilson’s disease in young patients presenting with concurrent neurological and hepatic manifestations. Early application of structured diagnostic criteria and prompt initiation of anti-copper therapy are essential to preventing irreversible organ damage and improving long-term prognosis.</p>
      </abstract>
      <kwd-group xml:lang="en" kwd-group-type="author-keywords">
        <title>Keywords</title>
        <kwd>Wilson’s disease</kwd>
        <kwd>dysarthria</kwd>
        <kwd>Kayser–Fleischer rings</kwd>
        <kwd>copper metabolism</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement>None</funding-statement>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Wilson’s disease (WD), first described by Samuel Alexander Kinnier Wilson in 1912, is a rare autosomal recessive inborn error of copper metabolism with an estimated prevalence of approximately 1 in 30,000 individuals worldwide.¹⁻³ The disorder results from pathogenic variants in the <italic>ATP7B</italic> gene, located on chromosome 13q14.3, which encodes a copper-transporting P-type ATPase essential for the incorporation of copper into ceruloplasmin and its subsequent excretion into bile. Impairment of this protein leads to progressive accumulation of copper within hepatocytes and, once hepatic storage capacity is exceeded, its deposition in extrahepatic tissues, principally the brain, cornea, and kidneys.⁴⁻⁶</p>
      <p>The clinical presentation of WD is highly variable, reflecting the distribution of copper deposition across different organ systems. Hepatic manifestations span a wide spectrum, ranging from asymptomatic elevation of transaminases to acute liver failure and end-stage cirrhosis. Neurological features, arising principally from copper deposition in the basal ganglia and other deep brain nuclei, include movement disorders, dysarthria, dysphagia, and cognitive impairment. Psychiatric disturbances, including personality changes, depression, and psychosis, may precede or accompany somatic symptoms. The Kayser–Fleischer ring, a golden-brown corneal deposit of copper visible on slit-lamp examination, is a characteristic ophthalmological sign that is present in virtually all patients with neurological involvement.⁴⁻⁶</p>
      <p>Despite its established clinical recognition, WD remains underdiagnosed, particularly in resource-limited settings, owing to its phenotypic diversity and the non-specific nature of its early manifestations. Accurate and timely diagnosis is of paramount importance, however, since WD is one of the few inherited metabolic disorders amenable to effective disease-modifying treatment. Copper-chelating agents such as D-penicillamine and trientine, as well as zinc salts, can stabilize and, in some cases, reverse organ dysfunction when initiated before irreversible structural damage occurs.⁷⁻¹⁰</p>
      <p>We present a case of WD in a young adult who came to medical attention with progressive dysarthria and abdominal distension attributable to concurrent neurological and hepatic involvement. This report illustrates the diagnostic approach using clinical, biochemical, ophthalmological, and neuroimaging criteria, and underscores the value of the Leipzig scoring system in confirming the diagnosis. Informed written consent was obtained from the patient before publication.</p>
    </sec>
    <sec>
      <title>Case Presentation</title>
      <p>A 25-year-old previously healthy male was referred to the outpatient department of Gulab Devi Hospital, Lahore, Pakistan, with a one-year history of progressive speech difficulty and gradually worsening abdominal distension. The speech impairment was insidious in onset and characterised by slurred articulation, monotonous prosody, nasal voice quality, hypophonia, and slow, effortful verbal output. Notably, language comprehension and expressive language function remained fully preserved, indicating a pure motor speech disorder (dysarthria) rather than a higher-order aphasic syndrome. Associated symptoms included sialorrhea, generalised fatigue, and intermittent inadvertent dropping of objects, suggestive of subtle distal motor dysfunction.</p>
      <p>General examination revealed jaundice and mild pallor. Abdominal examination demonstrated moderate ascites and marked splenomegaly consistent with portal hypertension. Slit-lamp biomicroscopy identified bilateral Kayser–Fleischer rings—golden-brown copper deposits at the Descemet membrane of the corneal periphery—a finding considered pathognomonic of neurological WD in the appropriate clinical context.</p>
      <p>Laboratory investigations disclosed markedly reduced serum ceruloplasmin at 5 mg/dL (reference range 20–60 mg/dL) and substantially elevated 24-hour urinary copper excretion at 328.3 μg/24 h (reference range &lt;60 μg/24 h), consistent with systemic copper overload (Tables 1 and 2). Liver function tests confirmed chronic hepatic injury (Table 3). Serological markers for viral hepatitis B and C were negative, and autoimmune hepatic markers were non-contributory, thereby excluding the principal alternative diagnoses (Table 4). Abdominal ultrasonography revealed hepatic cirrhosis, portal hypertension, ascites, and splenomegaly. Brain MRI demonstrated bilateral, symmetric T2-weighted hyperintensities involving the basal ganglia, thalami, and midbrain (Figure 1), a pattern characteristic of copper deposition and associated neurodegeneration in WD.</p>
      <p>Application of the Leipzig scoring system, which integrates Kayser–Fleischer ring status, serum ceruloplasmin, Coombs-negative haemolytic anaemia, urinary copper, neurological findings, and liver histology, yielded a total score of 8. A score of ≥4 is considered diagnostic of WD, and a score of ≥8 represents a high degree of diagnostic certainty.</p>
      <p>The patient was commenced on D-penicillamine 750 mg/day with pyridoxine supplementation to prevent drug-induced B6 deficiency, zinc acetate as an adjunct to reduce intestinal copper absorption, and a low-copper diet. At scheduled follow-up, the patient demonstrated satisfactory tolerance of therapy, stabilisation of neurological symptoms, and a gradual, clinically meaningful improvement in speech intelligibility.</p>
      <sec>
        <title>Table 1. Laboratory findings and reference ranges</title>
        <table-wrap id="tbl1">
          <label>Table 1</label>
          <table>
            <tbody>
              <tr>
                <td>Parameter</td>
                <td>Result</td>
                <td>Reference Range</td>
              </tr>
              <tr>
                <td>Serum Ceruloplasmin</td>
                <td>5 mg/dL</td>
                <td>20–60 mg/dL</td>
              </tr>
              <tr>
                <td>24-Hour Urinary Copper</td>
                <td>328.3 μg/24 h</td>
                <td></td>
              </tr>
              <tr>
                <td>Total Bilirubin</td>
                <td>1.5 mg/dL</td>
                <td>0.02–1.01 mg/dL</td>
              </tr>
              <tr>
                <td>Alanine Aminotransferase (ALT)</td>
                <td>64 U/L</td>
                <td>5–42 U/L</td>
              </tr>
              <tr>
                <td>Aspartate Aminotransferase (AST)</td>
                <td>79 U/L</td>
                <td>5–45 U/L</td>
              </tr>
              <tr>
                <td>HBsAg</td>
                <td>Negative</td>
                <td>Negative</td>
              </tr>
              <tr>
                <td>Anti-HCV</td>
                <td>Negative</td>
                <td>Negative</td>
              </tr>
              <tr>
                <td>Direct Coombs Test</td>
                <td>Negative</td>
                <td>Negative</td>
              </tr>
              <tr>
                <td>Indirect Coombs Test</td>
                <td>Negative</td>
                <td>Negative</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
          <italic>
            <bold>Axial T2-weighted brain MRI demonstrating bilateral symmetric hyperintensities within the basal ganglia, thalami, and midbrain (arrows). This characteristic neuroimaging pattern reflects copper deposition and associated neurodegeneration in Wilson’s disease.</bold>
          </italic>
        </p>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Wilson’s disease is a rare but treatable inborn error of copper metabolism caused by biallelic pathogenic variants in the <italic>ATP7B</italic> gene. The encoded protein, a copper-transporting P-type ATPase expressed predominantly in hepatocytes, is indispensable for both the synthesis of holoceruloplasmin and the biliary excretion of excess copper. Its functional loss results in progressive intrahepatic copper accumulation followed by systemic redistribution to the brain, cornea, kidneys, and other organs, producing the diverse clinical syndrome characterising WD.¹⁻³</p>
      <p>The case presented here is clinically noteworthy for the simultaneous presence of significant neurological and hepatic involvement at the time of initial presentation. The predominant neurological complaint was progressive dysarthria of the mixed spastic-hypokinetic type, reflecting concurrent corticobulbar and extrapyramidal dysfunction arising from copper deposition in the basal ganglia and their corticosubcortical connections. The co-occurrence of advanced hepatic disease, manifested as cirrhosis with portal hypertension and ascites, further supports the diagnosis. In clinical practice, neurological and hepatic presentations are often evaluated in parallel rather than as components of a single systemic disease, particularly in resource-constrained settings, potentially delaying definitive diagnosis.</p>
      <p>The Kayser–Fleischer ring, identified bilaterally on slit-lamp examination in the present patient, represents a pathognomonic sign of neurological WD in adults when combined with supportive biochemical and clinical findings. Its sensitivity approaches 95% in patients with neurological disease, though it may be absent in up to 50% of those with isolated hepatic presentations and is rarely observed in children under five years of age.⁴ The markedly depressed serum ceruloplasmin of 5 mg/dL and the substantially elevated 24-hour urinary copper excretion of 328.3 μg/24 h collectively constitute compelling biochemical evidence of systemic copper overload. It should be noted that ceruloplasmin, as an acute-phase reactant, may be artificially elevated during hepatic inflammation, and its sensitivity as a sole diagnostic criterion is therefore limited in isolation.⁵</p>
      <p>Neuroimaging in our patient revealed bilateral symmetric T2 hyperintensities involving the basal ganglia, thalami, and midbrain, a pattern that, while not pathognomonic, is highly characteristic of neurological WD and closely corresponds to the distribution of copper-mediated neurotoxicity. These findings are consistent with prior neuroimaging series documenting preferential involvement of the lenticular nuclei and midbrain tegmentum, structures that are particularly vulnerable to copper-induced oxidative injury.⁶ Magnetic resonance imaging may also demonstrate the “face of the giant panda” sign in the midbrain and the “face of the miniature panda” sign in the pons, though their presence is variable.</p>
      <p>The Leipzig scoring system, developed to standardise the diagnostic evaluation of WD by integrating clinical, ophthalmological, biochemical, and hepatological data, yielded a score of 8 in the present patient. This score substantially exceeds the threshold of ≥4 required for a definitive diagnosis, thereby precluding the need for liver biopsy in this case.⁵ The structured application of this scoring instrument is particularly valuable in centres where access to hepatic copper quantification or genetic testing may be limited.</p>
      <p>Regarding treatment, D-penicillamine remains one of the most widely employed copper-chelating agents in clinical practice owing to its efficacy in reducing total body copper burden through enhanced urinary excretion.⁷ Pyridoxine co-administration is standard practice given D-penicillamine’s anti-pyridoxine effect. Zinc salts exert their copper-lowering effect through a distinct mechanism, inducing metallothionein synthesis in enterocytes and thereby blocking intestinal copper absorption; zinc is generally preferred as maintenance therapy or in presymptomatic cases.⁸ The neurological response to chelation therapy is variable; improvement is more likely when treatment is initiated before the establishment of irreversible structural neurodegeneration, highlighting the importance of early diagnosis.⁹</p>
      <p>From an epidemiological perspective, the estimated prevalence of WD in Pakistan and neighbouring South Asian countries is believed to approximate or exceed that reported in European populations, partly attributable to higher rates of consanguineous marriage and the consequently increased frequency of homozygous or compound heterozygous genotypes among affected individuals.¹⁰ Awareness of this disorder among clinicians in the region is therefore of particular public health relevance.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>This case illustrates the importance of considering Wilson’s disease in the differential diagnosis of young patients presenting with progressive dysarthria, motor dysfunction, or unexplained chronic liver disease. A systematic diagnostic approach that integrates slit-lamp ophthalmology, serum ceruloplasmin measurement, 24-hour urinary copper excretion, neuroimaging, and the Leipzig scoring system permits confident diagnosis without recourse to invasive investigations in the majority of cases. Timely initiation of anti-copper therapy can stabilise neurological function, attenuate hepatic injury, and meaningfully improve quality of life. Heightened clinical awareness of this rare but eminently treatable disorder is essential to reduce the burden of delayed diagnosis and its attendant irreversible sequelae.</p>
      <p><bold>Ethical Approval: </bold>The IRB/EC approved this study via letter no.</p>
      <p><bold>Conflict of Interest: </bold>   None</p>
      <p><bold>Funding Source:</bold>     None</p>
      <sec>
        <title>Authors’ Contribution</title>
        <p>MB: Conception.</p>
        <p>FB, MBI: Design of the work.</p>
        <p>IA, MTS, MI: Data acquisition, analysis, or interpretation.</p>
        <p>MB, FB, IA, MTS, MI: Draft the work.</p>
        <p>MBI: Review critically for important intellectual content.</p>
        <p>All authors approve the version to be published.</p>
      </sec>
    </sec>
    <sec>
      <title>All authors agree to be accountable for all aspects of the work</title>
    </sec>
  </body>
  <back>
    <notes notes-type="author-contributions">
      <title>Author Contributions</title>
      <p>MB: Conception.</p>
      <p>FB, MBI: Design of the work.</p>
      <p>IA, MTS, MI: Data acquisition, analysis, or interpretation.</p>
      <p>MB, FB, IA, MTS, MI: Draft the work.</p>
      <p>MBI: Review critically for important intellectual content.</p>
      <p>All authors approve the version to be published.</p>
      <p>All authors agree to be accountable for all aspects of the work.</p>
    </notes>
    <notes notes-type="ethics-statement">
      <title>Ethics Statement</title>
      <p>not_applicable.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <label>1</label>
        <mixed-citation>Jones J, Sharma R, Silverstone L. Wilson’s disease. Radiopaedia.org. 2026;<pub-id pub-id-type="doi">10.53347/rID-5380</pub-id></mixed-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <mixed-citation>Immergluck J, Grant LM, Anilkumar AC. Wilson Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026; PMID: 28723019.</mixed-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <mixed-citation>Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The prevalence of Wilson’s disease: an update. Hepatol. 2020;71(2):722–32. <pub-id pub-id-type="doi">10.1002/hep</pub-id>. 30911.</mixed-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <mixed-citation>Pop TL, Grama A. New developments in the management of Wilson’s disease in children. Global Pediatrics. 2024;<pub-id pub-id-type="doi">10.1016/j.gpeds.2024.100142</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <mixed-citation>European Association for the Study of the Liver; European Reference Network on Rare Liver Diseases. EASL-ERN Clinical Practice Guidelines on Wilson’s disease. J Hepatol. 2025;<pub-id pub-id-type="doi">10.1016/j.jhep.2024.11.006</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <mixed-citation>Dev S, Kruse RL, Hamilton JP, Lutsenko S. Wilson disease: update on pathophysiology and treatment. Front Cell Dev Biol. 2022;<pub-id pub-id-type="doi">10.3389/fcell.2022.871877</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <mixed-citation>Weiss KH, Stremmel W, Gotthardt DN, Klemm D, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11(8):1028-35.</mixed-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <mixed-citation>Hawsawi YM. Novel variants associated with Wilson disease in Saudi families. J Gastroenterol Hepatol Res. 2019;8(10):1-8.</mixed-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <mixed-citation>Khan I, Iftikhar M, Khan SJ. Clinical and demographic profile of Wilson disease in young adults: a retrospective study at a tertiary care centre in Peshawar, Pakistan. Cureus. 2026;18(1):e100661.</mixed-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <mixed-citation>Kathawala M, Hirschfield GM. Insights into the management of Wilson’s disease. Ther Adv Gastroenterol. 2017;10(11):889–905.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
